Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NICE approves bendamustine for chronic lymphocytic leukaemia

By News team

Bendamustine is now recommended for the first-line treatment of some chronic cancer patients, according to guidance from the National Institute for Health and Clinical Excellence.

The drug, launched last August under the brand name Levact (Napp Pharmaceuticals), can be used in the NHS in England and Wales to treat patients with previously untreated chronic lymphocytic leukaemia (Binet stage B or C) who cannot receive fludarabine combination chemotherapy.

NICE rejected bendamustine in October 2010 for the treatment of non-Hodgkin’s lymphoma that is refractory to rituximab or a rituximab-containing regimen.

Citation: The Pharmaceutical Journal URI: 11069672

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.